Literature DB >> 15735745

PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.

Vladimir J N Bykov1, Nicole Zache, Helene Stridh, Jacob Westman, Jan Bergman, Galina Selivanova, Klas G Wiman.   

Abstract

Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1(MET) acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1(MET) resulted in a synergistic induction of tumor cell apoptosis and inhibition of human tumor xenograft growth in vivo in SCID mice. The induction of mutant p53 levels by chemotherapeutic drugs is likely to increase the sensitivity of tumor cells to PRIMA-1(MET). Thus, the combination of PRIMA-1(MET) with currently used chemotherapeutic drugs may represent a novel and more efficient therapeutic strategy for treatment of mutant p53-carrying tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735745     DOI: 10.1038/sj.onc.1208419

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  85 in total

1.  Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.

Authors:  Wei Zhang; Bin Yi; Chao Wang; Dongquan Chen; Sejong Bae; Shi Wei; Rong-Jun Guo; Changming Lu; Lisa L H Nguyen; Wei-Hsiung Yang; James W Lillard; Xingyi Zhang; Lizhong Wang; Runhua Liu
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

Review 2.  Targeting the p53 pathway.

Authors:  Vita M Golubovskaya; William G Cance
Journal:  Surg Oncol Clin N Am       Date:  2013-07-30       Impact factor: 3.495

3.  Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts.

Authors:  Mahmoud Alhosin; Abdulkhaleg Ibrahim; Abdelaziz Boukhari; Tanveer Sharif; Jean-Pierre Gies; Cyril Auger; Valérie B Schini-Kerth
Journal:  Invest New Drugs       Date:  2011-09-01       Impact factor: 3.850

4.  Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.

Authors:  Hui Chen; Kristin Gotimer; Cristabelle De Souza; Clifford G Tepper; Anthony N Karnezis; Gary S Leiserowitz; Jeremy Chien; Lloyd H Smith
Journal:  Gynecol Oncol       Date:  2020-04-04       Impact factor: 5.482

5.  Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.

Authors:  Satish K Ramraj; Sugantha P Elayapillai; Richard C Pelikan; Yan D Zhao; Zitha R Isingizwe; Amy L Kennedy; Stanley A Lightfoot; Doris M Benbrook
Journal:  Int J Cancer       Date:  2020-01-08       Impact factor: 7.396

Review 6.  Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

7.  p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.

Authors:  Luciana P Rangel; Giulia D S Ferretti; Caroline L Costa; Sarah M M V Andrade; Renato S Carvalho; Danielly C F Costa; Jerson L Silva
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

8.  Mutant p53 targeting by the low molecular weight compound STIMA-1.

Authors:  Nicole Zache; Jeremy M R Lambert; Nina Rökaeus; Jinfeng Shen; Pierre Hainaut; Jan Bergman; Klas G Wiman; Vladimir J N Bykov
Journal:  Mol Oncol       Date:  2008-03-07       Impact factor: 6.603

9.  The molecular genetics of breast cancer and targeted therapy.

Authors:  Rachel Suter; James A Marcum
Journal:  Biologics       Date:  2007-09

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.